Fate Therapeutics (FATE) Operating Income (2012 - 2026)
Fate Therapeutics (FATE) posted Operating Income of -$33.0 million for Q1 2026, up 4.96% on a QoQ basis from -$34.7 million in Q4 2025, and up 20.06% year-over-year from -$27.5 million in Q1 2025.
Fate Therapeutics (FATE) Operating Income (2012 - 2026) Analysis & Trends
Fate Therapeutics' Operating Income history runs 15 years deep, the most recent figure standing at -$33.0 million for Q1 2026.
- Quarterly Operating Income rose 20.06% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$139.4 million (up 30.46% YoY) and the FY2025 annual result came in at -$147.7 million, up 29.76% from the prior year.
- Operating Income was -$33.0 million for Q1 2026 at Fate Therapeutics, up from -$34.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$28.6 million in Q1 2023 and bottomed at -$86.4 million in Q3 2022.
- A 5-year average of -$52.3 million and a median of -$51.1 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income soared 61.6% — and 2024, when it slumped 78.61%.
- Fate Therapeutics' Operating Income stood at -$64.4 million in 2022, then advanced by 25.37% to -$48.1 million in 2023, then decreased by 28.44% to -$61.7 million in 2024, then soared by 43.77% to -$34.7 million in 2025, then advanced by 4.96% to -$33.0 million in 2026.
- Business Quant data shows FATE's Operating Income at -$33.0 million in Q1 2026, -$34.7 million in Q4 2025, and -$34.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -33.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.00 Mn |
| Dec 31, 2025 | -34.72 Mn |
| Sep 30, 2025 | -34.74 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -41.28 Mn |
| Dec 31, 2024 | -61.75 Mn |
| Sep 30, 2024 | -52.38 Mn |
| Jun 30, 2024 | -45.08 Mn |
| Mar 31, 2024 | -51.07 Mn |
| Dec 31, 2023 | -48.08 Mn |
| Sep 30, 2023 | -51.28 Mn |
| Jun 30, 2023 | -62.57 Mn |
| Mar 31, 2023 | -28.59 Mn |
| Dec 31, 2022 | -64.42 Mn |
| Sep 30, 2022 | -86.39 Mn |
| Jun 30, 2022 | -83.11 Mn |
| Mar 31, 2022 | -74.47 Mn |
| Dec 31, 2021 | -69.38 Mn |
| Sep 30, 2021 | -54.62 Mn |
| Jun 30, 2021 | -46.78 Mn |